Oncopeptides AB: Year-end Report 2018

Oncopeptides AB: Year-end Report 2018

PR Newswire

STOCKHOLM, Feb. 22, 2019

STOCKHOLM, Feb. 22, 2019 /PRNewswire/ -- Summary of Q4

Financial overview October 1December 31, 2018

Significant events during the period October 1 to December 31, 2018

Significant events after the reporting period

Financial overview of the group

SEK thousand 

2018 Oct - Dec 

2017 Oct - Dec 

2018 Jan - Dec 


2017 Jan - Dec 

Net sales





Operating loss





Loss before tax





Loss for the period





Earnings per share before and after dilution (SEK)





Cash flow from operating activities





Cash and cash equivalents at the end of the period 





Research & development costs/operating expenses %





Conference call for investors, analysts and the media

The Year-end Report for 2018 and an operational update will be presented by CEO Jakob Lindberg and members of Oncopeptides management team, Friday February 22, 2019 at 14:00 (CET).

The conference call will also be streamed via a link on the website: www.oncopeptides.com.

Phone numbers for participants from:

Sweden: +46-8-566-427 06Europe: +44-3333-009-270 USA: +1-833-526-83-82

Financial calendar 

Annual Report 2018:

Week 17, 2019

Annual General Meeting:    

May 21, 2019

Q1 Report 2019:  

May 21, 2019

Q2 Report 2019:

July 12, 2019

Q3 Report 2019:

November 19, 2019 

For more information, please contact:

Jakob Lindberg, CEO, Oncopeptides AB
E-mail: jakob.lindberg@oncopeptides.com
Telephone: +46-8-615-20-40

Rein Piir
Head of Investor Relations at OncopeptidesCell
phone: +46-70-853-72-92
E-mail: rein.piir@oncopeptides.com

 This information is information that Oncopeptides is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 08:00 CET on February 22, 2019. 

About Oncopeptides

Oncopeptides is a pharmaceutical company developing drugs for the treatment of cancer. The company is focusing on the development of the lead product candidate melflufen (Ygalo®), a novel peptide conjugated alkylator that selectively targets multiple myeloma belonging to the class of peptide-enhanced compounds. Melflufen is intended as an effective treatment of hematological cancers, and in particular multiple myeloma. The goal with the current clinical study program is to demonstrate better results from treatment with melflufen compared with established alternative drugs for patients with multiple myeloma. Melflufen will potentially provide physicians with a new treatment option for patients suffering from this serious disease.

More information is available on www.oncopeptides.com.

This information was brought to you by Cision http://news.cision.com


The following files are available for download:


Year end report 2018 (PDF)


Press Release (PDF)

Voltar noticias em Inglês